First-in-human trial of focused ultrasound to reduce schizophrenia hallucinations

A first‑in‑human clinical trial using focused ultrasound to reduce hallucinations in schizophrenia has begun. The study targets patients who continue to hear voices despite antipsychotic treatment.

Auditory hallucinations affect more than 70 % of people with schizophrenia, and roughly 40 % of those patients still experience persistent hallucinations. This underscores the urgent need for new therapeutic approaches.